Howie Que
Foot & Ankle Surgery · Encinitas, CANPI 1477934909
Payments from drug & device makers
Across 221 payments — averaging $86.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotissue Holdings Inc.$4K
- Aroa Biosurgery Incorporated$3K
- Trimed, Inc.$3K
- Smith+Nephew$1K
- Stryker$1K
- Treace Medical Concepts, Inc.$875
- plus $6K from 29 others
What the payments were for
- Consulting fees$1,5008%
- Speaking & faculty fees$2,00010%
- Travel & lodging$3,03716%
- Food & beverage$12,54166%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotissue Holdings Inc. | 32 | $3,897 |
| Aroa Biosurgery Incorporated | 13 | $3,006 |
| Trimed, Inc. | 7 | $2,528 |
| Smith+Nephew | 55 | $1,238 |
| Stryker | 7 | $1,068 |
| Treace Medical Concepts, Inc. | 9 | $875 |
| Medline Industries LP | 4 | $718 |
| Kerecis Limited | 4 | $661 |
| Bioventus LLC | 25 | $623 |
| AbbVie(2 entities) | 20 | $529 |
| Acera Surgical, Inc. | 4 | $446 |
| Johnson & Johnson(2 entities) | 3 | $375 |
| Pacira Pharmaceuticals Incorporated | 3 | $367 |
| Amgen | 4 | $355 |
| Elevate Surgical Co | 2 | $267 |
| Bone Support Inc. | 2 | $262 |
| Novartis | 2 | $197 |
| Edwards Lifesciences | 1 | $195 |
| Zimmer Biomet | 3 | $161 |
| Medtronic | 1 | $160 |
| Integra Lifesciences Corporation | 2 | $130 |
| Acumed LLC | 1 | $124 |
| Ossio Inc | 1 | $122 |
| Pfizer | 1 | $121 |
| Flower Orthopedics Coporation | 1 | $119 |
| AstraZeneca | 1 | $115 |
| Merck | 1 | $105 |
| International Life Sciences | 1 | $84 |
| Tactile Systems Technology Inc | 3 | $51 |
| Arthrosurface Incorporated | 1 | $51 |
| Assertio Therapeutics, Inc. | 2 | $33 |
| Nevro Corp. | 1 | $32 |
| Hartmann USA, Inc. | 2 | $31 |
| Next Science LLC | 1 | $18 |
| Acell, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tools - FPS$2,147
- Kerecis Omega3 Marigen$1,426
- Kerecis Omega3 SurgiClose$776
- Lapiplasty System$677
- COLLAGENASE SANTYL$611
- MEDLINE INDUSTRIES, INC.$575
- Kerecis SurgiClose$547
- NEOX$470
- CLARIX$470
- Restrata Wound Matrix$430
- Kerecis Omega3 GraftGuide$418
- MEDLINE$415
- EXPAREL$367
- KRYSTEXXA$350
- PROSTEP MICA$308
- CERAMENTBONE VOID FILLER$262
- CERAMENT G$262
- SAPIEN 3 Ultra RESILIA$195
- Exogen Ultrasound Bone Healing System$190
- FLEXBAND$172
How this compares
$19,079 in reported general payments places this provider in the 90th percentile of 1,126 foot & ankle surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SantylCollagenase Clostridium Hist. | 41 | $35,585 |
| Gabapentin | 26 | $237 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Smith+NephewSantyl | $1,238 | $35,58541 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,126 foot & ankle surgery providers in California.
Other foot & ankle surgery in Encinitas
- John ZimmermanBakersfield$4.6M
- Eric GizaSacramento$3.7M
- Thomas HarrisPasadena$3M
- Felix SigalLos Angeles$2.2M
- Thomas ChangSanta Rosa$2.1M
- Michael CoughlinSan Francisco$1.6M
- Vladimir ZeetserEncino$677K
- Jason NowakRedding$526K
- Candice BradyCamarillo$462K
- Andrew HsuOrange$456K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.